Navigation Links
Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
Date:8/15/2012

es, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, the number of orphan GPCRs that Omeros expects to unlock; the potential indications of the orphans GPCRs unlocked by Omeros; Omeros' potential patent rights for each unlocked orphan GPCR; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
2. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
3. Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
6. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
7. A new class of electron interactions in quantum systems
8. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
9. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
10. Notice of Redemption and Withdrawal of Class of Securities from Listing on the NYSE
11. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 In late 2012, ... to speak to doctors in China about Appearance Medicine ... NZ, this was her first trip to lecture in China, ... visited Guangzhou and Fuzhou, home to 12 and 7 million ... is very high at this point in time. As Dr. ...
(Date:5/16/2013)... 16, 2013  HealthSparq, a trusted provider of ... largest regional health plans, will debut a new ... (AHIP) Institute 2013 conference on June 13.  The ... how health insurance companies across the country are ... marketplace demands for increased healthcare transparency. ...
(Date:5/16/2013)... 2013 On average, developing a new ... billion dollars. Despite this investment, less than 10% of ... is your clinical trial design optimally structured to balance ... , Dr. Frederic Sax, Global Head of the Center ... of data, information and technology in upfront clinical trial ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... Oral Therapeutic for IBD with Novel Mode of ... ChemoCentryx, Inc., today announced that data from the ... in Crohn,s disease Trial) Phase II/III clinical trial ... disease will be presented in an oral session ...
... to present Phase 2 data on perifosine for ... Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... therapy and oncology, today announced that results supporting ... compound, AEZS-108, in prostate cancer, will be presented ...
... Commitment to Sustainable Innovation., Accelerates LS9,s Entry into the ... ... South San Francisco, CA (PRWEB) -- LS9, Inc., the Renewable ... and Gamble (NYSE: PG), one of world,s largest consumer products ...
Cached Biology Technology:ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting 2AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting 3LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership 2
(Date:5/16/2013)... Bethesda, MD (May 17, 2013) Illustrating a ... the American Gastroenterological Association (AGA) Research Foundation ... Future Student Research Fellowship Award recipients. Supported by ... Kidney Diseases (NIDDK), this new award helps underrepresented ... digestive disease and nutrition research. , "By establishing ...
(Date:5/16/2013)... Northwestern University scientists have shown a gene involved in ... proper function of the circadian clock. , In ... found the gene, called Ataxin-2, keeps the clock responsible ... the gene, the rhythm of the fruit fly,s sleep-wake ... schedule difficult for the fly. , The discovery ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Gene involved in neurodegeneration keeps clock running 2
... weed that clogs waterways around the world has at least ... for boats and submarines. The Brazilian fern Salvinia ... part because its surface is dotted with oddly shaped hairs ... afloat. In the November 1 issue of the ...
... Unisys Corporation (NYSE: UIS ) is assisting ... the first pedestrian border crossing in El Paso, Texas, that ... radio frequency identification (RFID) technology to more efficiently identify and ... Additionally, ten fingerprint biometric capture devices are included in the ...
... From a bike path in Montana to a backwater ... out last June to capture high-resolution images for the ... broader participation in their efforts to document global biodiversity ... the solstice week of Dec. 19-26., The GigaBlitz ...
Cached Biology News:Plant with 'eggbeater' testure inspires waterproof coating 2Plant with 'eggbeater' testure inspires waterproof coating 3Customs and Border Protection Opens Pedestrian Border Crossing System in El Paso with Support from Unisys 2GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 2GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 3
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... T4 DNA Ligase catalyzes the joining of ... and the 3´-hydroxyl groups of adjacent nucleotides ... (1). The enzyme has also been shown ... either a DNA or RNA strand in ...
... The EC3 Darkroom is designed for ... The EC3 systems offer direct control ... and darkroom settings by hand , A ... the best system for all fluorescent and ...
Biology Products: